Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients -- Hodi et al. 105 (8): 3005 Data Supplement - HTML Page - index.htslp -- Proceedings of the National Academy of Sciences

Hodi et al. 10.1073/pnas.0712237105.

Supporting Information

Files in this Data Supplement:

Table 1. Characteristics of metastatic melanoma patients that received Ipilumimab after GVAX

Patient	Disease sites	Interval from GVAX to Ipilumimab	No. of Ipilumimab infusions	Toxicities	RECIST	Survival
MEL 1	Liver, lung, kidney, soft tissue	6 weeks	1	Grade I constitutional	Progression	5 mos.
MEL 2	Liver, lung, lymph nodes, soft tissue	5 weeks	1	Grade I rash, Grade II constitutional	Progression	6 weeks
MEL 3	Lung	4 weeks	3	Grade I rash Grade I retinal	Stable, 4 mos.	Lost to follow-up
MEL 4	Lung, lymph nodes, soft tissues	4 weeks	16	Grade I rash	Partial response, 34+ mos.	Alive
MEL 5	Lung, lymph nodes, soft tissues	6 weeks	3	Grade I rash	Stable, 6 mos.	18 mos.
MEL 6	Bone, lymph nodes, skin	7 weeks	6	Grade I rash, Grade II sarcoidosis	Stable, 25+ mos.	Alive
MEL 7	Liver, lung, lymph nodes	7 weeks	11	Grade I rash, Grade II constitutional	Stable, 25+ mos.	Alive
MEL 8	Bone, liver, lung, lymph nodes, soft tissues	4 weeks	2	Grade I rash	Stable, 4 mos.	11 mos.
MEL 9	Liver, lung, lymph nodes	4 mos.	3	Grade I rash	Partial response, 24+ mos.	Alive
MEL 10	Liver, lung, lymph nodes, skin	4 weeks	1	Grade I rash	Progression	2 mos.
MEL 11	Liver, lung, lymph nodes	8 weeks	3	Grade II diarrhea	Partial response, 21+ mos.	Alive

Table 2. Characteristics of metastatic ovarian carcinoma patients that received Ipilumimab after GVAX

Patient	Disease sites	Interval from GVAX to Ipilumimab	No. of Ipilumimab infusions	Toxicities	RECIST	Survival
OV 1	Brain, liver, diaphragm, lymph nodes, peritoneum	3 years	1	Grade I rash, Grade III diarrhea	Progression	20 mos.
OV 2	Peritoneum	2 mos.	2	Grade I rash, Grade II constitutional	Stable, 4 mos.	23 mos.
OV 3	Serosa	3 mos.	1	Grade I rash	Stable, 2 mos.	Alive (40 mos.)
OV 4	Liver	55 mos.	1	Grade I constitutional	Progression	16 mos.
OV 5	Liver, lung, omentum, lymph nodes	1 mo	11	Grade I rash	Partial response, 35+ mos.	Alive
OV 6	Pre-sacral mass, lung, omentum, lymph nodes	39 mos.	1	Grade III diarrhea, Sweet's syndrome	Progression	5 mos.
OV 7	Liver, lung, pelvis, intra-abdominal	1 mo	1	Grade I rash	Progression	15 mos.
OV 8	Mesentery, peritoneum, soft tissues	9 mos.	1	Grade I rash	Progression	Alive (21 mos.)
OV 9	Lymph nodes	18 mos.	3	Grade I rash Grade I constitutional	Stable, 6+ mos.	Alive

Fig. 6. CTLA-4 antibody blockade provokes the development of a Sweet's syndrome-like disorder. (A) Severe neutrophilic hypersensitivity (H&E). (Magnification: ´10.) (B) Granuloma-annulare-like features (H&E). (Magnification: ´20.)